5WEP
Crystal structure of fosfomycin resistance protein FosA3 with inhibitor (ANY1) bound
5WEP の概要
| エントリーDOI | 10.2210/pdb5wep/pdb |
| 関連するPDBエントリー | 5VB0 |
| 分子名称 | FosA3, 6,6'-(4-nitro-1H-pyrazole-3,5-diyl)bis(3-bromopyrazolo[1,5-a]pyrimidin-2(1H)-one), ZINC ION (3 entities in total) |
| 機能のキーワード | fosfomycin, fosa, fosa3, glutathione s-transferase, any1, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
| 由来する生物種 | Escherichia coli |
| タンパク質・核酸の鎖数 | 2 |
| 化学式量合計 | 33697.39 |
| 構造登録者 | |
| 主引用文献 | Tomich, A.D.,Klontz, E.H.,Deredge, D.,Barnard, J.P.,McElheny, C.L.,Eshbach, M.L.,Weisz, O.A.,Wintrode, P.,Doi, Y.,Sundberg, E.J.,Sluis-Cremer, N. Small-Molecule Inhibitor of FosA Expands Fosfomycin Activity to Multidrug-Resistant Gram-Negative Pathogens. Antimicrob. Agents Chemother., 63:-, 2019 Cited by PubMed Abstract: The spread of multidrug or extensively drug-resistant Gram-negative bacteria is a serious public health issue. There are too few new antibiotics in development to combat the threat of multidrug-resistant infections, and consequently the rate of increasing antibiotic resistance is outpacing the drug development process. This fundamentally threatens our ability to treat common infectious diseases. Fosfomycin (FOM) has an established track record of safety in humans and is highly active against , including multidrug-resistant strains. However, many other Gram-negative pathogens, including the "priority pathogens" and , are inherently resistant to FOM due to the chromosomal gene, which directs expression of a metal-dependent glutathione -transferase (FosA) that metabolizes FOM. In this study, we describe the discovery and biochemical and structural characterization of ANY1 (3-bromo-6-[3-(3-bromo-2-oxo-1H-pyrazolo[1,5-a]pyrimidin-6-yl)-4-nitro-1H-pyrazol-5-yl]-1H-pyrazolo[1,5-a]pyrimidin-2-one), a small-molecule active-site inhibitor of FosA. Importantly, ANY1 potentiates FOM activity in representative Gram-negative pathogens. Collectively, our study outlines a new strategy to expand FOM activity to a broader spectrum of Gram-negative pathogens, including multidrug-resistant strains. PubMed: 30642934DOI: 10.1128/AAC.01524-18 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (3.502 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






